文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

肾脏替代治疗启动策略对慢性肾脏病患者结局的影响:STARRT-AKI试验的二次分析

Impact of renal-replacement therapy strategies on outcomes for patients with chronic kidney disease: a secondary analysis of the STARRT-AKI trial.
PubMed 文献 · Intensive Care Med · 2022-11-04
一句话结论STARRT-AKI二次分析显示,合并慢性肾脏病(CKD)的急性肾损伤患者采用加速启动肾脏替代治疗策略,90天依赖透析的几率增加三倍以上(aOR 3.18;95%CI 1.41-7.91)。

该研究为STARRT-AKI多国随机试验的二次分析,纳入1121例有住院前估算肾小球滤过率(eGFR)数据的患者,以eGFR≤59 mL/min/1.73 m2定义CKD,其中432例(38.5%)存在CKD。主要结局为90天全因死亡率,次要结局包括90天肾脏替代治疗(RRT)依赖和RRT-free天数。CKD患者90天死亡率47% vs 40%(p<0.001),但协变量校正后无显著差异(aOR 1.05;95%CI 0.79-1.41);CKD患者90天RRT依赖比例更高(14% vs 8%;aOR 1.89;95%CI 1.05-3.43)。CKD状态未改变RRT启动策略对90天死亡率的影响;在CKD患者中,加速策略较标准策略显著增加90天RRT依赖(aOR 3.18;95%CI 1.41-7.91),而无CKD患者中无此效应(aOR 0.71;95%CI 0.34-1.47;交互作用P=0.009)。结论提示,对合并CKD的急性肾损伤患者,加速启动RRT策略与更高的90天RRT依赖风险相关。

要点

  • 在合并CKD的急性肾损伤患者中,加速启动RRT策略与90天RRT依赖风险显著增加相关(aOR 3.18;95%CI 1.41-7.91)。
  • 在无CKD的患者中,加速启动RRT策略对90天RRT依赖无显著影响(aOR 0.71;95%CI 0.34-1.47),交互作用P=0.009。
  • CKD状态未改变RRT启动策略对90天死亡率的影响。
  • CKD患者90天全因死亡率47% vs 40%(p<0.001),但校正协变量后差异无统计学意义(aOR 1.05;95%CI 0.79-1.41)。
  • CKD患者90天RRT依赖比例更高(14% vs 8%;aOR 1.89;95%CI 1.05-3.43)。

适用人群与场景

  • STARRT-AKI试验中具有住院前eGFR记录的患者;CKD定义为eGFR≤59 mL/min/1.73 m2。
  • 共纳入1121例患者,其中432例(38.5%)为CKD。

诊断标准与关键阈值

  • CKD定义为住院前eGFR≤59 mL/min/1.73 m2。

研究设计与关键结果

  • 研究类型:多国随机试验的二次分析;样本量1121例,其中CKD 432例(38.5%)。
  • CKD与非CKD患者基线血肌酐中位数(IQR)分别为130(114-160)µmol/L与76(64-90)µmol/L;CKD患者年龄更大,心血管合并症和糖尿病更常见。
  • CKD患者90天全因死亡率47% vs 40%(p<0.001);校正协变量后aOR 1.05(95%CI 0.79-1.41)。
  • CKD患者90天RRT依赖比例14% vs 8%(aOR 1.89;95%CI 1.05-3.43)。
  • CKD状态未改变RRT启动策略对90天死亡率的影响。
  • 在CKD患者中,加速启动RRT策略与标准策略相比,90天RRT依赖aOR 3.18(95%CI 1.41-7.91);在无CKD患者中aOR 0.71(95%CI 0.34-1.47);交互作用P=0.009。

证据类型、等级与局限

  • 证据类型:多国随机对照试验(STARRT-AKI)的二次分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于合并CKD的急性肾损伤患者,加速启动RRT策略与90天RRT依赖风险增加相关(aOR 3.18;95%CI 1.41-7.91),而无CKD患者中未见此效应(aOR 0.71;95%CI 0.34-1.47;交互作用P=0.009)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: To assess whether pre-existing chronic kidney disease (CKD) modified the relationship between the strategy for renal-replacement theraphy (RRT) initiation and clinical outcomes in the STARRT-AKI trial.

METHODS: This was a secondary analysis of a multi-national randomized trial. We included patients who had documented pre-existing estimated glomerular filtration rate (eGFR) data prior to hospitalization, and we defined CKD as an eGFR ≤ 59 mL/min/1.73 m2. The primary outcome was all-cause mortality at 90 days. Secondary outcomes included RRT dependence and RRT-free days at 90 days. We used logistic and linear regression and interaction testing to explore the effect of RRT initiation strategy on outcomes by CKD status.

RESULTS: We studied 1121 patients who had pre-hospital measures of kidney function. Of these, 432 patients (38.5%) had CKD. The median (IQR) baseline serum creatinine was 130 (114-160) and 76 (64-90) µmol/L for those with and without CKD, respectively. Patients with CKD were older and more likely to have cardiovascular comorbidities and diabetes mellitus. Patients with CKD had higher 90-day mortality (47% vs. 40%, p < 0.001) compared to those without CKD, though this was not significant after covariate adjustment (adjusted odds ratio [aOR], 1.05; 95% CI, 0.79-1.41). Patients with CKD were more likely to remain RRT dependent at 90 days (14% vs. 8%; aOR, 1.89; 95% CI, 1.05-3.43). CKD status did not modify the effect of RRT initiation strategy on 90-day mortality. Among patients with CKD, allocation to the accelerated strategy conferred more than threefold greater odds of RRT dependence at 90 days (aOR 3.18; 95% CI, 1.41-7.91) compared with the standard strategy, whereas RRT initiation strategy had no effect on this outcome among those without CKD (aOR 0.71; 95% CI, 0.34-1.47, p value for interaction, 0.009).

CONCLUSION: In this secondary analysis of the STARRT-AKI trial, an accelerated strategy of RRT initiation conferred a higher risk of 90-day RRT dependence among patients with pre-existing CKD; however, no effect was observed in the absence of CKD.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Bagshaw SM, Neto AS, Smith O, et al. Impact of renal-replacement therapy strategies on outcomes for patients with chronic kidney disease: a secondary analysis of the STARRT-AKI trial. Intensive Care Med. 2022. PMID: 36331570. doi:10.1007/s00134-022-06912-w

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。